Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Background & Aims: Response-guided therapy has been con- P = 0.407). The rate of HBeAg seroconversion with HBV DNA
firmed to be an effective strategy for the treatment of chronic <2000 IU/ml at EOF were similar for arms B, C and D (17.9%,
hepatitis C in the pegylated interferon (PegIFN) era, but no ran- 23.9% and 25.0% respectively). For patients with HBsAg
domized trial utilizing this strategy has been conducted in <1500 IU/ml or HBV DNA <105 copies/ml at week 24, 38.4% and
chronic hepatitis B. 37.0% achieved HBeAg seroconversion with HBV DNA <2000 IU/
Methods: In this open-label, multicenter, randomized trial, ml at EOF respectively.
HBeAg positive patients were treated with PegIFN (180 lg/week) Conclusions: Patients with HBsAg <1500 IU/ml or HBV DNA
for 24 weeks. Early responders (HBsAg <1500 IU/ml and HBV <105 copies/ml at week 24 would benefit from continued PegIFN
DNA <105 copies/ml at week 24) received PegIFN for a further treatment. Extending the duration of PegIFN with or without add-
24 weeks (arm A), while non-early responders were randomized ing adefovir did not show superiority over 48 weeks PegIFN
to PegIFN for another 24 weeks (arm B), another 72 weeks (arm monotherapy.
C) or PegIFN for another 72 weeks plus adefovir for 36 weeks Lay summary: Extending the duration of pegylated interferon
(arm D). The primary endpoint was the change of quantitative (PegIFN) alfa-2a is not recommended in HBeAg positive patients
HBsAg from baseline to the end of follow-up (EOF). as treatment extension beyond 48 weeks did not show convinc-
Results: For non-early responders, 96-week PegIFN monotherapy ing benefit. Patients who achieved HBsAg <1500 IU/ml or HBV
did not lead to a greater reduction of HBsAg from baseline to EOF, DNA <105 copies/ml after 24-week PegIFNa-2a showed satisfac-
compared with 48-week PegIFN (0.71 vs. 0.67 log10 IU/ml, tory outcome after the withdrawal of finite PegIFNa-2a
treatment.
Clinical Trial Number: NCT01086085.
Keywords: Antiviral therapy; Hepatitis B; Clinical trial.
Received 13 January 2016; received in revised form 21 April 2016; accepted 13 May
2016 European Association for the Study of the Liver. Published
2016; available online 26 May 2016 by Elsevier B.V. This is an open access article under the CC BY-NC-
Corresponding author. Address: Hepatology Unit, Nanfang Hospital, Southern ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Medical University, Guangzhou 510515, China. Tel.: +86 20 61641941; fax: +86
20 62786530.
E-mail address: jlhousmu@163.com (J. Hou).
y
These authors contributed equally as joint first authors.
Introduction
Abbreviations: ADV, adefovir; AEs, adverse events; ALT, alanine aminotransferase;
BMI, body mass index; CHB, chronic hepatitis B; EOF, end of follow-up; EOT, end
of treatment; ETV, entecavir; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; Chronic hepatitis B (CHB) caused by hepatitis B virus (HBV) infec-
HBeAb, hepatitis B e antibody; HBsAb, hepatitis B surface antibody; HBsAg, tion is a major public health problem that affects more than
hepatitis B surface antigen; ITT, intention to treat; NAs, nucleot(s)ide analogs; 350 million people worldwide. Liver cirrhosis, liver failure and
PEIU, Paul Ehrlich international units; PegIFN, pegylated interferon; RGT,
response-guided therapy; ULN, upper limit of normal.
hepatocellular carcinoma are well-known sequelae of CHB [1].
D
PegIFN-2a 180 g/week Follow-up
Materials and methods
ADV 10 mg
Study design and treatment protocol
once daily
Screened
N = 373
Enrollment
N = 265
Withdraw consent n = 1
Completed first 24
week treatment
N = 264
Randomization
Arm B p <0.001
3.0 6.0
from baseline, log10 IU/ml
Arm C
2.0 4.0
1.5 3.0
1.0 2.0
0.5 1.0
0.0 0.89 0.33 0.28 0.34 1.52 0.40 0.36 0.45 1.53 0.87 0.72 0.87 1.15 0.67 0.71 0.64
0.0 3.60 2.38 2.09 1.83 4.82 2.62 2.27 2.45 4.79 3.18 3.01 3.72 3.28 2.34 2.68 2.83
Week 12 Week 24 EOT EOF Week 12 Week 24 EOT EOF
No. of subjects being followed: No. of subjects being followed:
66 67 67 64 66 67 67 64 65 67 56 58 62 64 52 53 66 67 67 64 66 67 67 64 65 67 56 58 62 64 52 53
Fig. 3. Mean decline of HBsAg (A) and HBV DNA (B) from baseline to 24 weeks post-treatment. p value was calculated from a Students t test between early responder
and non-early responder. Last observation carried forward procedure was used to impute the missing data pertaining to the treatment period. EOT, end of treatment; EOF,
end of follow-up.
Efficacy in Non-early responders (Arms B, C and D) and 26.9%), as compared to arm B (14.9% and 13.4%) but without
statistical significance. When we combined the arm C and arm D,
At the end of treatment i.e., all patients with 96 weeks PegIFN therapy, the HBeAg loss
From week 24 to EOT, further decline of HBsAg was observed in and HBeAg seroconversion rate was significantly higher com-
the three groups (0.47 log10 IU/ml, 0.36 log10 IU/ml and pared to the group of patients receiving the 48 weeks regimen
0.42 log10 IU/ml in arms B, C and D, respectively). There was (arm B).
no significant difference in the decrease of HBsAg from baseline Adding on ADV from week 29 to week 64 resulted in a tempo-
to EOT in arm B, when compared with that observed in arms C rary improvement of viral suppression with a higher HBV DNA
and D, respectively (B vs. C, p = 0.746; B vs. D, p = 0.461). reduction from baseline to week 72 (arm C vs. Arm D, 2.49 vs.
At EOT, 96 weeks of therapy with PegIFNa-2a in combination 3.99 log10 copies/ml, p <0.001). However, the HBV DNA unde-
with ADV (arm D) resulted in a significantly higher proportion of tectability rate at EOT was similar between arms C and D.
patients achieving HBeAg loss (35.9% vs. 14.9%, p = 0.022) and
seroconversion (31.3% vs. 13.4%, p = 0.041) compared with At the end of follow-up
48 weeks PegIFNa-2a monotherapy in arm B (Table 3). The rates Partial rebound of quantitative HBsAg from EOT to EOF was
of HBeAg loss and seroconversion were higher in arm C (28.4% observed in each arm after the stop of PegIFN (Fig. 3A). There
Safety
%
The safety analysis included 265 patients who received at least 1
50
HBV DNA <2000 IU/ml at EOF
38.8% total of 262 patients (98.9%) experienced AEs with more AEs
40 38.4% 37.0% 36.8%
35.0% being mild to moderate in severity. Four patients discontinued
combined with
Fig. 4. Rates of response at end of follow-up according to HBsAg and/or HBV RGT is a promising approach which has been successfully applied
DNA at week 24. to the treatment of chronic hepatitis C. To the best of our